



SCOPE FLUIDICS

Q2 2026 UPDATE

6 October 2026

DISCLAIMERS



This presentation (“Presentation”) contains basic information about Scope Fluidics S.A. (“the Company”) and the Scope Fluidics S.A. Group (“the Group”).

This presentation has been prepared solely for the purpose of providing basic information about the Group and its operations. It does not present complete data regarding the Group’s operations, financial condition, assets, or legal status, which may be required to make an investment decision regarding the Group or the financial instruments of its subsidiaries. The Company has taken measures to ensure that the data presented is fully reliable; however, it cannot and should not be treated as such. All forecasts, opinions, and projections contained in the Presentation, including the Company’s projections, opinions, and forecasts, were prepared as part of routine analytical activities and should not be treated as information approved by any third party. Although measures have been taken to ensure that the facts stated in the Presentation are accurate and that the forecasts, opinions, and projections are reliable and reasonable, the Company has not verified their completeness or accuracy.

Consequently, neither the Company nor any of its shareholders or advisors, their affiliates, members of governing bodies, or employees shall be liable, on any basis whatsoever, for the content of the Presentation.

When making investment decisions or acting for any other purpose, one should not rely on the information contained in the Presentation, including with respect to its accuracy, reliability, and completeness. None of the entities listed above accepts any liability, on any basis, for any damages arising from the use of this document and the information contained therein.

The statements contained in the Presentation should not be treated as assurances or guarantees by the Company or as commitments or promises regarding the Group’s future financial or operating results. The content of the Presentation does not constitute, nor should it be treated as, investment, legal, or tax advice. Recipients of the Presentation should independently seek appropriate investment, legal, or tax advice.

This presentation does not constitute an offer, in particular within the meaning of the Act of July 29, 2005, on Public Offerings and the Conditions for Introducing Financial Instruments to an Organized Trading System, and on Public Companies (Journal of Laws, consolidated text 2013.1382 as amended) or the Act of April 23, 1964—Civil Code (Journal of Laws, consolidated text 2014.121, as amended), a recommendation, or an invitation to subscribe for or purchase bonds.

Neither the Presentation nor any part thereof constitutes any contract or any obligation regarding the performance of such a contract. The Company reserves the right to amend or supplement the Presentation at any time, although it is under no obligation to do so, nor is it obligated to make any updates or corrections to the content of the Presentation, or to provide additional information about the Company or the Group.

UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS

MANAGEMENT BOARD OF SCOPE FLUIDICS



MARCIN IZYDORZAK

VICE PRESIDENT

- Co-founder of Scope Fluidics
- Responsible for clinical trials, IP, production and regulatory areas
- Gained experience in technology companies, scientific institutes and pharmaceutical companies



PROF. PIOTR GARSTECKI

CEO

- Co-founder of Scope Fluidics
- Responsible for development of innovative technologies and building the organization
- Experience in scientific and technological projects in Poland and in the USA, specialized in soft matter physics and microfluidic technologies




SZYMON RUTA

VICE PRESIDENT, CFO

- Responsible for financial division, investor relations and M&A transactions
- Experienced in managing of capital groups, cooperation with capital markets and execution of M&A transactions

VENTURE STUDIO - OUR VALUES AND VISION FOR SUCCESS

- We address **global challenges in healthcare** and develop technologies with real, global impact
- We aim at **+USD 10⁹ markets and develop technologies that can readily be leveraged by large, multinational and global med-tech operators**
- We develop companies as attractive acquisition targets for global strategic investors with valuations in multiples of USD 100 mln



Corporate structure supports execution of M&A transactions



Each project in Scope Fluidics' Group is **developed in a separate, legal entity (SPV)**



Each subsidiary is focused on the R&D activities and has the full ownership of all the IP relevant to its project, employment, commercial contracts, and all relevant certifications



Scope Fluidics provides SPVs with back-office functions, such as HR, finance, reporting, legal, regulatory, etc.



Sold to Bio-Rad Laboratories
August 2022

SUBSIDIARY #1



Started in 2012



100% ownership of the SPVs

SUBSIDIARY #2



Started in 2017



SUBSIDIARY #3

EDOCERA
Prevention and ongoing diagnostics for patients at risk of stroke

Started in 2024



SUBSIDIARY #4


HYBOLIC
Comprehensive solution for patients with metabolic syndrome

Started in 2024



How we operate at Scope Discovery

Systemic selection and development of new projects



SCOPE FLUIDICS

KEY EVENTS 2026 - YTD

KEY EVENTS 2026 - YTD

- ✓ **IVDR certification** secured for **BACTEROMIC UNI** and **UNI-FAST Panels**
 - ✓ **3 distribution agreements** signed, covering **12 European markets**
 - ✓ **Production site secured** and **semi-automated production line** development continued
 - ✓ **PBC clinical study agreement** signed, advancing the **next BACTEROMIC Panel** toward certification
 - ✓ **U.S. patent granted** for BACTEROMIC's **Microfluidic Chip technology**
 - ✓ **Funding agreement signed with PARP** for the **HYBOLIC project**
 - ✓ **First sales proceeds from BACTEROMIC**, amounting to approximately PLN 0.3 million
- 

SCOPE FLUIDICS

OUR KEY PROJECT

Bacteria Become Increasingly Resistant to Existing Antibiotics

- WHO warns on **growing Antimicrobial Resistance (AMR)** and antibiotics becoming ineffective
- Antibiotics prescribed randomly and patients not following recommendations further contribute to the problem
- **Antimicrobial susceptibility testing (AST)** identifies the most effective antibiotic for a bacterial infection, enabling targeted treatment, improving patient outcomes, and helping to slow AMR progress.

AMR as leading cause of death

169M

deaths associated with
AMR in 2025–2050*

Comprehensive AST diagnostics
are fundamental to a sustainable solution.

Microbiology is a legacy of complexity. No single AST solution provides enough versatility.

Labs need speed, information and unified approach to AST at cost enabling routine use –
for every patient, regardless of sample type.

Standard Bacterial Infections (Isolates)

*Vitek 2 (bioMérieux) · Phoenix (BD/Waters) · Sensititre
(ThermoFisher) · MicroScan (Beckman Coulter)*

- Mainstream segment – 50M+ tests/year
- 12-20 antibiotics per panel
- Slow time to result (12-24h)
- Isolates only — no simple PBC/sepsis coverage
- Legacy design, largely unchanged for years



Critical Bloodstream Infections (Positive Blood Cultures – PBC)

*Q-linea · Specific Reveal (bioMérieux) · Gradientech · Selux Dx
(closed)*

- Growing segment, need for fast results
- 12-30 antibiotics per Panel
- Low hardware throughput: 8-12 panels/device
- High price €100+ per test, no isolates synergy
- Selux Dx — the one true rival — ceased operations in 2025 (high entry cost, ~\$400k/set)



Bacteromic

One platform for both segments

- Isolates + PBC on one Platform
- Up to 60 antibiotics in a single test —
10x more information than market leader
- Fast results
- Low single-digit € COGS for Panels enables
flexible, competitive pricing in both segments



No Longer a Vision: a First in Class, **Complete AST Platform**

One Rapid Platform for Two Segments: Isolates and PBC

One system, same-day results, precision antibiotic therapy guidance

Accessible on every front

Easy to use, strong unit economics for flexibility across segments & high-throughput for efficient use of lab space

First test = final AST report

AST across all relevant antibiotics at once.
No panel guessing. No retesting.



Isolates & PBC in one box

Yes

Final antibiogram after first test

Yes

Cost savings across segments

Yes

Market leaders

No

No

No

Protecting Technology that Makes Bacteromic Unique



METHOD AND SYSTEM FOR RAPIDLY TESTING ANTIMICROBIAL SUSCEPTIBILITY

Rapid signal analysis method of determining the minimum inhibitory concentration (MIC) based on standard measurements in the shortest possible time to date



METHOD AND SYSTEM FOR PREDICTION OF MICROORGANISM GROWTH USING ARTIFICIAL INTELLIGENCE

The computer-implemented method for real-time prediction of microorganism growth or growth inhibition of a microorganism inoculum using artificial intelligence (AI)



MICROFLUIDIC CHIP

The invention is intended for microbiological testing cards, particularly for microbial identification and antimicrobial susceptibility testing (AST)



INCUBATION SEGMENT WITH AN UNVENTED GAS CAVITY IN A MICROFLUIDIC CHIP

The object of the invention is the geometry of a single incubation segment in a microfluidic chip, suitable for microbiological research



A SYRINGE-PLUG AND A CARTRIDGE FOR ANALYTIC ASSAYS COMPRISING SUCH A SYRINGE-PLUG

Provided for sealing a sample chamber of a cartridge for analytic assays, comprises a tank pre-filled with a non-aquatic liquid



Recent updates:

June 2024 – US patent for „Incubation segment in microfluidic chip”

August 2024 – CN patent for „Incubation segment in microfluidic chip”


October 2024 – CN patent for „Method and System for rapidly testing...”

April 2025 – EPO patent for „Method and System for prediction of microorganism...”

May 2026 – US patent granted for „Microfluidic Chip”

Further IP processes in progress

Clear Regulatory Pathway Across EU and US Markets



Securing commercial-scale manufacturing capacity to meet future demand and effects of scale

ANALYZER & FILLING DEVICE



Cooperation with BIT Analytical Solutions

Germany-based OEM specialized in electronic hardware assembly

CONSUMABLES

PILOT PRODUCTION LINE:

~100k panels/year



COMMERCIAL PRODUCTION LINE:


up to ~750k panels/year

- Ongoing line setup in a new facility, production readiness for ~350k panels/year expected latest in H1'27
- Expansion to 750k/year achievable within several months upon and subject to business decision



Initiating clinical presence & signing first distribution agreements

Done, ongoing and planned pilot trials in European countries.
Planned first evaluations in USA in 2026



- Strong advantage of **true MIC values**
- **Strong performance** - results exceeding >90% CA/EA
- **Results faster by even 24h** (for FAST products)
- **Convenient workflow, easy to use** even for less skilled staff
- System **easy to adopt & occupies less space** in the lab

SIGNED DISTRIBUTION AGREEMENTS

- ELTA 90 MR (Romania)



- Mefamed (Turkey)



- Biomedica Medizinprodukte
(10 European Countries)



ONGOING DISCUSSIONS & NEGOTIATIONS WITH SELECTED PARTIES IN OTHER REGIONS

Perella Weinberg Partners – top tier advisor for Dx & AST



Perella Weinberg Partners
is a leading US-based boutique
investment bank with strong
expertise in healthcare sector

- Since October 2025, Perella supports Scope Fluidics in preparation and execution of the M&A process with Bacteromic project
- PWP is a highly experienced partner with a profound understanding of the diagnostics and rapid AST segment, as well as a broad relationship network – enabling access to key stakeholders and potential investors.
- PWP has advised a number of companies in M&A processes, also publicly-traded clients, with transactions value amounting over USD 1 trillion, including USD 200+ billion in healthcare since 2011

Selected healthcare transactions

 **SPECIFIC**

Advised Specific, rapid
AST, on the sale to
bioMérieux for
USD 425 M

 **ACCELERATE**
DIAGNOSTICS

Advised Accelerate, rapid
AST, on the sale of
assets to Indaba for
USD 41 M

 **QUIDEL**

Ortho
Clinical Diagnostics

Advised Quidel on
acquisition of Ortho,
for
USD 8.1 B

ThermoFisher
SCIENTIFIC

astorg.

Advised ThermoFisher
on the sale of
Microbiology division to
Astorg PE
USD 1.1 B

DISCOVERY & NEW PROJECTS



Comprehensive solution for stroke risk monitoring



PROBLEM



Stroke treatment is possible only within
critical ≤ 6 hour window.
1 in 3 strokes has an unknown onset.

However, **strokes often go undetected for hours.**
After 6h window, typically high-success rate procedure comes
with too many side effects – and risks exceed potential benefits.

Stroke's occurrence time is critical
to apply potentially life-saving treatment

MARKET FIT

1,000+ interviews and opinions collected from patients,
caregivers and clinicians in Poland and the US.

KEY OPINION LEADERS

We work with key opinion leaders in neurology and stroke
care in Poland and the US.

SOLUTION



Identifying stroke early to enable timely
possibility of potentially life-saving
treatment within the critical ≤ 6 h window.

Leveraging AI to analyze multiple
physiological signals simultaneously,
enabling pre-symptomatic detection of
stroke onset.

PROGRESS & MILESTONES



Technology verification



1st prototype




grant agreement to be signed

MARKET OPPORTUNITY



\$4-10
billion TAM

8.5-10%
CAGR



*Illustrative-only visualisation. CAGR: stroke diagnostics market, 2026–2033
(Coherent Market Insights).*

Comprehensive solution for monitoring of metabolic parameters

PROBLEM



Metabolic dysfunction precedes diabetes, obesity, fatty liver, heart disease and dementia by up to a decade – **26% of adults worldwide are insulin resistant.**

Yet we still track only the late signal – glucose. In a large consumer testing dataset, **over 50% had high fasting insulin but normal glucose.**

People already pay to test themselves (**500k Function Health members, \$365/year**), but no tool shows how their metabolism responds day by day.

SOLUTION



A wearable patch measuring insulin and glucose continuously, and an AI app that turns them into a personal metabolic baseline – showing how every meal, workout or drug changes your metabolism.

MARKET OPPORTUNITY



\$20+
billion TAM

20+%
CAGR

PROGRESS & MILESTONES

- ✓ FENG grant signed with PARP – up to PLN 14.4M (≈ €3.4M) non-dilutive funding
- ⌚ Technology verification
- ⌚ First multi-analyte sensor prototype – experimental verification in progress



Illustrative-only visualisation.

2nd edition

Scope Fluidics Fellowship 2026.

A transformative program turning breakthrough ideas into ventures with lasting impact.

12

Fellows work alongside Scope Discovery analysts and our Primary Market Research team to uncover problems worth solving.

11

Mentors: top scientists, physicians, and business leaders guide fellows and help sharpen early ideas into lasting ventures.

4

Tracks: interdisciplinary teams spanning Medical, Data & AI, Scientific, and Business expertise.

3

Months: an intensive, full-immersion program moving from Discovery through the Concept Phase.





SCOPE FLUIDICS

Consolidated financials



30 June 2026

Scope Fluidics consolidated financial statements at 30 June 2026

Statement of profit or loss and other comprehensive income [PLN thousand]

	Jun 2026	Jun 2025
Revenue	59	676
Operating expenses	(25,980)	(19,285)
Depreciation and amortisation	(1,218)	(986)
Raw materials and consumables used	(1,754)	(1,821)
External services	(10,579)	(6,666)
Taxes and charges	(298)	(148)
Wages and salaries	(8,445)	(7,181)
Social security and other employee benefits	(1,947)	(1,171)
Other expenses by nature	(1,739)	(1,312)
Gross loss	(25,921)	(18,609)
Other operating income (expenses)	(361)	20
Operating loss	(26,282)	(18,589)
Finance income	3,163	2,600
Finance costs	(131)	(3,417)
Loss before tax	(23,250)	19,406
Income tax	(351)	(145)
Net loss	(23,601)	(19,551)

Towards the end of the six-month period ended 30 June 2026, the Group received first proceeds from the sale of the BACTEROMIC system to Turkish distributor Mefamed, amounting to nearly PLN 0.3 million. As the product was released from the warehouse for delivery in the following month, the related revenue was recognised in July 2026.

The Group's operating expenses rose by PLN 6.7 million (35%) year on year, driven primarily by a higher cost of external services (up PLN 3.9 million; 59%), combined with an increase in wages and salaries (up PLN 1.3 million; 18%).

The overall increase in the cost of external services was mainly due to higher costs of consulting services at Edocera, Hybolic and Bacteromic.

The primary reason behind the increase in wages and salaries was a headcount increase across the Group, including at Edocera and Hybolic as those companies expanded over the past year. Headcount under employment contracts and civil-law contracts stood at 175 in the six months ended 30 June 2026, compared with 132 in the corresponding period of 2025.

Scope Fluidics consolidated financial statements at 30 June 2026

Statement of profit or loss and other comprehensive income [PLN thousand]

	Jun 2026	Jun 2025
Revenue	59	676
Operating expenses	(25,980)	(19,285)
Depreciation and amortisation	(1,218)	(986)
Raw materials and consumables used	(1,754)	(1,821)
External services	(10,579)	(6,666)
Taxes and charges	(298)	(148)
Wages and salaries	(8,445)	(7,181)
Social security and other employee benefits	(1,947)	(1,171)
Other expenses by nature	(1,739)	(1,312)
Gross loss	(25,921)	(18,609)
Other operating income (expenses)	(361)	20
Operating loss	(26,282)	(18,589)
Finance income	3,163	2,600
Finance costs	(131)	(3,417)
Loss before tax	(23,250)	19,406
Income tax	(351)	(145)
Net loss	(23,601)	(19,551)

In the six months ended 30 June 2026, the Group generated PLN 3.1 million in finance income on invested cash, including PLN 1.9 million in gains on the remeasurement of bond fund units and PLN 0.9 million in interest on bank deposits.

Scope Fluidics consolidated financial statements at 30 June 2026

Statement of financial position [PLN thousand]



	30 Jun 2026	31 Dec 2025
Non-current assets, including:	40,715	29,265
<i>Property, plant and equipment</i>	10,546	8,752
<i>Capitalised development costs</i>	26,556	17,670
Current assets, including:	130,080	166,670
<i>Cash in hand and at banks</i>	53,623	93,153
<i>Investment fund units</i>	65,651	63,772
Total assets	170,795	195,935
Equity	138,830	162,431
Liabilities and provisions for liabilities, including:	31,965	33,504
<i>Share-based payment liabilities</i>	14,643	15,321
<i>Deferred income – advance payment from Mefamed</i>	298	0
Total equity and liabilities	170,795	195,935

Non-current assets increased by PLN 11.5 million (39%) relative to year-end 2025, mainly on account of the capitalisation of development costs (up PLN 8.9 million; 50%). The increase also reflected a PLN 1.8 million (20%) rise in property, plant and equipment, driven by purchases of machinery and equipment forming part of a production line for the commercial-scale manufacture of BACTEROMIC system panels.

The most significant component of the Group's current assets was liquid resources totalling nearly PLN 120 million. As at 30 June 2026, these comprised cash in hand and at bank of PLN 53.6 million and investment fund units of PLN 65.7 million.

The PLN 0.7 million (4%) decrease in the phantom share liability was driven mainly by a decline in the market multiple for the medtech peer group.

Deferred income included nearly PLN 0.3 million of proceeds from the sale of the BACTEROMIC system to Turkish distributor Mefamed. As the product was released from the warehouse for delivery in the following month, the related revenue was recognised in July 2026.



SCOPE FLUIDICS

Separate financials



30 June 2026

Scope Fluidics separate financial statements at 30 June 2026

Statement of profit or loss and other comprehensive income [PLN thousand]

	Jun 2026	Jun 2025
Revenue	3,437	3,028
Operating expenses	(11,301)	(9,660)
Depreciation and amortisation	(738)	(621)
Raw materials and consumables used	(338)	(215)
External services	(4,211)	(4,046)
Taxes and charges	(46)	(48)
Wages and salaries	(4,755)	(3,661)
Social security and other employee benefits	(928)	(651)
Other expenses by nature	(285)	(418)
Gross loss	(7,864)	(6,632)
Other operating income (expenses)	(123)	4
Operating loss	(7,987)	(6,628)
Finance income	2,675	2,410
Finance costs	(123)	(3,401)
Loss before tax	(5,435)	(7,619)
Income tax	(351)	(145)
Net loss	(5,786)	(7,764)
Total comprehensive income	(5,786)	(7,764)

In the reporting period, the Company generated PLN 3.4 million in revenue from administrative, legal and financial support services provided to subsidiaries, including PLN 2.6 million from Bacteromic sp. z o.o., PLN 0.5 million from Edocera sp. z o.o. and PLN 0.3 million from Hybolic sp. z o.o.

The Company's operating expenses rose by PLN 1.6 million (17%) year on year, due mainly to headcount expansion and the resulting PLN 1.1 million (30%) increase in wages and salaries.

In the six months ended 30 June 2026, the Company generated PLN 2.7 million in finance income on invested cash, including PLN 1.9 million in gains on the remeasurement of bond fund units and PLN 0.8 million in interest on bank deposits.

Scope Fluidics separate financial statements at 30 June 2026

Statement of financial position [PLN thousand]

	30 Jun 2026	31 Dec 2025
Non-current assets, including:	160,650	142,361
<i>Investments in subsidiaries</i>	<i>156,479</i>	<i>138,157</i>
Current assets, including:	102,731	128,935
<i>Cash in hand and at banks</i>	<i>34,797</i>	<i>62,910</i>
<i>Investment fund units</i>	<i>65,651</i>	<i>63,772</i>
Total assets	263,381	271,296
Equity	240,868	246,654
Liabilities and provisions for liabilities, including:	22,513	24,642
<i>Share-based payment liabilities</i>	<i>14,643</i>	<i>15,321</i>
Total equity and liabilities	263,381	271,296

The Company's non-current assets increased by PLN 18.3 million (13%) relative to year-end 2025, primarily reflecting higher investments in subsidiaries. During the reporting period, the carrying amount of investments in subsidiaries grew by PLN 19 million, including PLN 15 million in Bacteromic and PLN 2 million in each of Hybolic and Edocera.

The most significant component of the Company's current assets was liquid resources totalling over PLN 100 million. As at 30 June 2026, these comprised cash in hand and at bank of PLN 34.8 million and investment fund units of PLN 65.7 million.

Q&A session



MARCIN IZYDORZAK

VICE PRESIDENT




PROF. PIOTR GARSTECKI

CEO



SZYMON RUTA

VICE PRESIDENT, CFO





THANK YOU

INVESTOR RELATIONS

relacjeinwestorskie@scopefluidics.com